Thursday, 5 November 2026European Markets

AVANCE GAS HOLDING And FRONTLINE Have A High Dividend Yield And Return On Equity In The Oil & Gas Midstream Industry.

Loading stream...

(VIANEWS) - AVANCE GAS HOLDING (AGAS.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Oil & Gas Midstream industry.

Financial Asset Price Forward Dividend Yield Return on Equity
AVANCE GAS HOLDING (AGAS.OL) kr124.80 22.06% 17.24%
FRONTLINE (FRO.OL) kr249.50 10.59% 33.1%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. AVANCE GAS HOLDING (AGAS.OL)

22.06% Forward Dividend Yield and 17.24% Return On Equity

Avance Gas Holding Ltd, together with its subsidiaries, engages in the transportation of liquefied petroleum gas (LPG). The company transports LPG from the Persian Gulf and the United States Gulf/the United States East Coast to destinations in Europe, South America, India, and Asia. As of December 31, 2022, it owned and operated through a fleet of twelve very large gas carriers and four dual-fuel LPG newbuildings. The company was founded in 2007 and is based in Hamilton, Bermuda. Avance Gas Holding Ltd operates as a subsidiary of Hemen Holding Ltd.

Earnings Per Share

As for profitability, AVANCE GAS HOLDING has a trailing twelve months EPS of kr18.95.

PE Ratio

AVANCE GAS HOLDING has a trailing twelve months price to earnings ratio of 6.59. Meaning, the purchaser of the share is investing kr6.59 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.24%.

More news about AVANCE GAS HOLDING.

2. FRONTLINE (FRO.OL)

10.59% Forward Dividend Yield and 33.1% Return On Equity

Frontline plc, a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2022, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Limassol, Cyprus.

Earnings Per Share

As for profitability, FRONTLINE has a trailing twelve months EPS of kr37.48.

PE Ratio

FRONTLINE has a trailing twelve months price to earnings ratio of 6.66. Meaning, the purchaser of the share is investing kr6.66 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.1%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 15, 2023, the estimated forward annual dividend rate is 20.26 and the estimated forward annual dividend yield is 10.59%.

Yearly Top and Bottom Value

FRONTLINE's stock is valued at kr249.50 at 01:40 EST, way above its 52-week high of kr205.50.

Moving Average

FRONTLINE's value is way higher than its 50-day moving average of kr163.61 and way above its 200-day moving average of kr155.83.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FRONTLINE's EBITDA is 192.84.

More news about FRONTLINE.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com